Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001470831-26-000214 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2026-02-23	2026-02-19	BBIO	Kumar Neil	CEO, Dir	S - Sale	$71.39	-28.1K	234.5K	-11%	-$2.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-19	S	D	18,923	$71.03	243,581	D	—	—	(F2) Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2	Common	Common Stock	2026-02-19	S	D	8,528	$72.08	235,053	D	—	—	(F3) Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3	Common	Common Stock	2026-02-19	S	D	602	$72.80	234,451	D	—	—	(F4) Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.